[go: up one dir, main page]

ECSP055985A - Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis - Google Patents

Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis

Info

Publication number
ECSP055985A
ECSP055985A EC2005005985A ECSP055985A ECSP055985A EC SP055985 A ECSP055985 A EC SP055985A EC 2005005985 A EC2005005985 A EC 2005005985A EC SP055985 A ECSP055985 A EC SP055985A EC SP055985 A ECSP055985 A EC SP055985A
Authority
EC
Ecuador
Prior art keywords
treatment
acid derivatives
ciclohexanocarbonil
aminobutírico
ilmetoxi
Prior art date
Application number
EC2005005985A
Other languages
English (en)
Inventor
Heiner Glombik
Dirk Gretzke
Eugen Falk
Jochen Goerlitzer
Stefanie Keil
Hans-Ludwig Schaefer
Christian Stapper
Wolfgang Wendler
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of ECSP055985A publication Critical patent/ECSP055985A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La invención se refiere a derivados de aminoácidos sustituidos con cicloalquilo y a sus sales fisiológicamente aceptables y derivados fisiológicamente funcionales. Se describen compuestos de la fórmula I, en donde los radicales tienen los significados indicados, sus sales fisiológicamente compatibles y métodos para su preparación. Los compuestos de la invención se adecuan, por ejemplo, para el tratamiento y/o la prevención de trastornos del metabolismo de los ácidos grasos y trastornos del aprovechamiento de glucosa, así como trastornos en los que la resistencia a insulina juega un papel.
EC2005005985A 2003-02-27 2005-08-26 Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis ECSP055985A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ECSP055985A true ECSP055985A (es) 2006-01-16

Family

ID=32920629

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2005005986A ECSP055986A (es) 2003-02-27 2005-08-26 Derivados de ácido 3-(2-fenil-oxazol-4-ilmetoxi)ciclohexilmetoxiacético y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis
EC2005005985A ECSP055985A (es) 2003-02-27 2005-08-26 Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2005005986A ECSP055986A (es) 2003-02-27 2005-08-26 Derivados de ácido 3-(2-fenil-oxazol-4-ilmetoxi)ciclohexilmetoxiacético y compuestos relacionados utilizados como moduladores de ppar para tratar diabetes de tipo 2 y arterioesclerosis

Country Status (34)

Country Link
US (5) US7259177B2 (es)
EP (3) EP1599453B1 (es)
JP (3) JP2006519193A (es)
KR (3) KR20050106462A (es)
CN (3) CN100439347C (es)
AR (3) AR043433A1 (es)
AT (3) ATE365159T1 (es)
AU (3) AU2004215673B2 (es)
BR (3) BRPI0407758A (es)
CA (3) CA2517381A1 (es)
CL (2) CL2004000392A1 (es)
CO (2) CO5690580A2 (es)
DE (4) DE10308355A1 (es)
DK (3) DK1599452T3 (es)
EC (2) ECSP055986A (es)
ES (3) ES2287700T3 (es)
HR (3) HRP20050743A2 (es)
IL (2) IL170314A (es)
MA (3) MA27737A1 (es)
MX (3) MXPA05008995A (es)
NO (3) NO20054396L (es)
OA (2) OA13034A (es)
PA (1) PA8596801A1 (es)
PE (3) PE20050293A1 (es)
PL (3) PL378130A1 (es)
PT (3) PT1599453E (es)
RS (1) RS20050594A (es)
RU (3) RU2005130002A (es)
SA (1) SA04250153A (es)
TN (2) TNSN05204A1 (es)
TW (3) TW200508210A (es)
UY (2) UY28210A1 (es)
WO (3) WO2004076427A1 (es)
ZA (2) ZA200505768B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
EP1931337B1 (en) 2005-09-29 2013-10-23 Sanofi Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
WO2008018138A1 (en) 2006-08-10 2008-02-14 Wood One Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
DK2246343T3 (en) 2008-02-29 2016-08-15 Nissan Chemical Ind Ltd Process for the preparation of thiophene compound and its intermediate
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116165857A (zh) 2017-12-13 2023-05-26 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs) 1996-01-17 1998-11-11 Novo Nordisk A/S Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
EP1108713A4 (en) * 1998-08-27 2006-04-05 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE COMPONENT
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
AU3956900A (en) 1999-04-16 2000-11-02 Boehringer Ingelheim International Gmbh Substituted imidazoles, their preparation and use
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
CA2371308A1 (en) * 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
JP2002543200A (ja) 1999-04-30 2002-12-17 ニューロゲン コーポレイション ９Ｈ−ピリミド［４、５−ｂ］インドール誘導体：ＣＲＦ１特異性リガンド
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
US6399640B1 (en) 1999-06-18 2002-06-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
AU774071B2 (en) * 1999-09-01 2004-06-17 Sanofi-Aventis Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU773777B2 (en) 1999-12-03 2004-06-03 Astrazeneca Ab Crystalline form of (S)-2 ethoxy-3-(4-(2-(4-methanesulfonyloxyphenyl) ethoxy) phenyl) propanoic acid
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CZ20023234A3 (cs) 2000-03-31 2003-01-15 Probiodrug Ag Léčivo proti diabetu
AU4882801A (en) 2000-04-25 2001-11-07 Kyorin Pharmaceutical Co. Ltd. Novel stable crystal of thiazolidinedione derivative and process for producing the same
CA2407538C (en) 2000-04-28 2007-01-09 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
JP2003534377A (ja) 2000-05-30 2003-11-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作働薬
HRP20020968A2 (en) 2000-06-09 2005-02-28 Aventis Pharma Deutschland Gmbh Acylphenyl urea derivatives, methods for the production therof and use thereof as a medicament
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
US6982278B2 (en) 2000-08-23 2006-01-03 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
EA200300286A1 (ru) * 2000-08-23 2003-08-28 Эли Лилли Энд Компани Агонисты активируемых пероксисомальным пролифератором рецепторов
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
WO2002046146A1 (fr) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
BR0116325A (pt) 2000-12-21 2003-10-14 Aventis Pharma Gmbh 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios
JP3491635B2 (ja) * 2000-12-25 2004-01-26 小野薬品工業株式会社 ジヒドロナフタレン誘導体化合物およびその化合物を有効成分とする薬剤
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
SK14922003A3 (sk) * 2001-06-07 2005-04-01 Eli Lilly And Company Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
PL208515B1 (pl) 2001-08-31 2011-05-31 Sanofi Aventis Deutschland Pochodne diarylocykloalkilowe, środki lecznicze zawierające te związki oraz ich zastosowanie jako aktywatorów PPAR
JP2005517008A (ja) 2002-02-05 2005-06-09 イーライ・リリー・アンド・カンパニー Ｐｐａｒモジュレーターとして用いるためのウレアリンカー誘導体
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
UY28209A1 (es) 2004-09-30
ES2326418T3 (es) 2009-10-09
AU2004215673A1 (en) 2004-09-10
RU2005129995A (ru) 2006-01-27
PE20050292A1 (es) 2005-05-24
JP2006519199A (ja) 2006-08-24
ECSP055986A (es) 2006-01-16
DE502004009453D1 (de) 2009-06-18
US7335671B2 (en) 2008-02-26
AU2004215673B2 (en) 2009-10-01
US7872034B2 (en) 2011-01-18
KR20050105492A (ko) 2005-11-04
ATE435217T1 (de) 2009-07-15
US20080167354A1 (en) 2008-07-10
DE502004009690D1 (de) 2009-08-13
PL378130A1 (pl) 2006-03-06
CN1753881A (zh) 2006-03-29
AR043427A1 (es) 2005-07-27
PT1599453E (pt) 2009-07-14
MXPA05008951A (es) 2005-11-04
RU2005130002A (ru) 2006-01-27
MA27737A1 (fr) 2006-02-01
PL378437A1 (pl) 2006-04-03
TW200500349A (en) 2005-01-01
US20050101637A1 (en) 2005-05-12
BRPI0407814A (pt) 2006-02-14
PT1599455E (pt) 2009-09-29
ES2287700T3 (es) 2007-12-16
PT1599452E (pt) 2007-09-12
EP1599453A1 (de) 2005-11-30
ES2329366T3 (es) 2009-11-25
EP1599452B1 (de) 2007-06-20
CN1753879A (zh) 2006-03-29
DK1599455T3 (da) 2009-11-09
OA13035A (en) 2006-11-10
PE20040959A1 (es) 2005-01-17
MXPA05008995A (es) 2005-10-18
TNSN05204A1 (en) 2007-06-11
MXPA05008988A (es) 2005-10-18
EP1599455A1 (de) 2005-11-30
PE20050293A1 (es) 2005-05-24
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
AU2004215677B2 (en) 2010-01-07
CA2517386A1 (en) 2004-09-10
CA2517381A1 (en) 2004-09-10
US20050215596A1 (en) 2005-09-29
CO5690578A2 (es) 2006-10-31
SA04250153A (ar) 2005-12-03
TW200508210A (en) 2005-03-01
AU2004215672B2 (en) 2010-01-07
WO2004076426A1 (de) 2004-09-10
RS20050594A (sr) 2007-12-31
CL2004000392A1 (es) 2005-04-22
US7365084B2 (en) 2008-04-29
MA27742A1 (fr) 2006-02-01
US20040209920A1 (en) 2004-10-21
NO20054396D0 (no) 2005-09-22
CN100439345C (zh) 2008-12-03
DK1599453T3 (da) 2009-08-24
CN1756748A (zh) 2006-04-05
AU2004215677A1 (en) 2004-09-10
IL170314A (en) 2010-11-30
DE502004004139D1 (de) 2007-08-02
EP1599455B1 (de) 2009-07-01
KR20050106462A (ko) 2005-11-09
CL2004000391A1 (es) 2005-01-07
WO2004076428A1 (de) 2004-09-10
US7259177B2 (en) 2007-08-21
BRPI0407907A (pt) 2006-02-14
WO2004076427A1 (de) 2004-09-10
ATE430738T1 (de) 2009-05-15
CA2516620A1 (en) 2004-09-10
OA13034A (en) 2006-11-10
PL377735A1 (pl) 2006-02-20
UY28210A1 (es) 2004-09-30
NO20054398D0 (no) 2005-09-22
EP1599452A1 (de) 2005-11-30
US20080015238A1 (en) 2008-01-17
BRPI0407758A (pt) 2006-02-14
ZA200505768B (en) 2005-11-23
CN100439347C (zh) 2008-12-03
HRP20050744A2 (en) 2006-09-30
KR20050106461A (ko) 2005-11-09
TNSN05206A1 (en) 2007-06-11
EP1599453B1 (de) 2009-05-06
TW200510352A (en) 2005-03-16
DK1599452T3 (da) 2007-10-01
ZA200505765B (en) 2006-05-31
RU2005129992A (ru) 2006-02-10
JP2006519193A (ja) 2006-08-24
DE10308355A1 (de) 2004-12-23
AR043433A1 (es) 2005-07-27
NO20054398L (no) 2005-11-02
AU2004215672A1 (en) 2004-09-10
AR043432A1 (es) 2005-07-27
CN100398526C (zh) 2008-07-02
MA27736A1 (fr) 2006-02-01
NO20054396L (no) 2005-11-11
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
HRP20050742A2 (en) 2006-09-30
NO20054408D0 (no) 2005-09-22
ATE365159T1 (de) 2007-07-15
CO5690580A2 (es) 2006-10-31
JP2006519194A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
ECSP055985A (es) Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis
CO6270312A2 (es) Moduladores de gpr40 bifenilo-sustituidos
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
SV2004001691A (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen compuestos y sus usos
GT200300075AA (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 1 de la solicitud no. pi-20030075)
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
DOP2006000204A (es) Derivados de fenil-[1,2,4]oxadiazol-5-ona con fenilo, procedimientos para su preparacion y su uso como productos farmaceuticos
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
UY28122A1 (es) Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
WO2010045258A3 (en) Spirocyclic gpr40 modulators
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
UY29258A1 (es) Ácidos hidroxibifenilcarboxílicos y derivados, procedimientos para prepararlos y su uso
PA8607201A1 (es) Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso
ECSP044994A (es) Derivados de diarilcicloalquilo, procedimientos para su preparacion y su utilización como agentes activadores del ppar
PA8635301A1 (es) Derivados sustituidos del dioxido de oxazolbenzoisotiazol, procedimiento para su preparacion y su uso
MX385354B (es) Sales de xantilio 3,6-disustituidas.
UY31968A (es) Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY30284A1 (es) Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
PA8596701A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
BRPI0606502A2 (pt) compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos
UY29846A1 (es) N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter